METHYLPREDNISOLONE ACETATE
GLUCOCORTICOSTEROIDS·TRICHINOSIS·+43
PAR HEALTH USA,
Indication
Humoral hypercalcemia of malignancy
Humoral hypercalcemia of malignancy is a systemic metabolic paraneoplastic syndrome that occurs in patients with advanced cancers, most commonly squamous cell carcinomas, renal cell carcinoma, ovarian cancer, and breast carcinoma. Read more about Humoral hypercalcemia of malignancy
385 drugs 179 manufacturers
Drugs that treat it
Common Humoral hypercalcemia of malignancy therapies.
PREDNISONE
GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
QUALITY CARE
HYDROCORTISONE
GLUCOCORTICOSTEROIDS·TRICHINOSIS·+51
AVPAK
PREDNISONE
GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
UNIT DOSE SERVI
ZOLEDRONIC ACID
HYPERCALCEMIA AGENTS·HUMORAL HYPERCALCEMIA OF MALIGNANCY·+2
INGENUS PHARMAC
DEPO-MEDROL (methylprednisolone acetate)
GLUCOCORTICOSTEROIDS·TRICHINOSIS·+43
A-S MEDICATION
DEXAMETHASONE
GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+61
A-S MEDICATION
DEXAMETHASONE SODIUM PHOSPHATE
GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+60
A-S MEDICATION
KENALOG-40 (triamcinolone acetonide)
GLUCOCORTICOSTEROIDS·TRICHINOSIS·+53
A-S MEDICATION
Filter & compare in the drug finder →Opens the drug finder with Humoral hypercalcemia of malignancy preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHumoral hypercalcemia of malignancy is a systemic metabolic paraneoplastic syndrome that occurs in patients with advanced cancers, most commonly squamous cell carcinomas, renal cell carcinoma, ovarian cancer, and breast carcinoma.
It affects the skeletal and renal systems through the tumor-driven secretion of circulating factors, overwhelmingly parathyroid hormone-related protein (PTHrP), without requiring direct skeletal metastases.
Clinically and pathophysiologically, circulating PTHrP binds to parathyroid hormone receptors, triggering profound osteoclastic bone resorption and stimulating renal tubular calcium reabsorption while promoting phosphate wasting, which leads to severe, often life-threatening elevations in serum calcium.
- nih.gov
Humoral hypercalcemia of malignancy is a systemic metabolic paraneoplastic syndrome that occurs in patients with advanced cancers, most commonly squamous cell carcinomas, renal cell carcinoma, ovarian cancer, and breast carcinoma
- nih.gov
Humoral hypercalcemia of malignancy is a systemic metabolic paraneoplastic syndrome that occurs in patients with advanced cancers, most commonly squamous cell carcinomas, renal cell carcinoma, ovarian cancer, and breast carcinoma
- nih.gov
It affects the skeletal and renal systems through the tumor-driven secretion of circulating factors, overwhelmingly parathyroid hormone-related protein (PTHrP), without requiring direct skeletal metastases
- endocrine.org
It affects the skeletal and renal systems through the tumor-driven secretion of circulating factors, overwhelmingly parathyroid hormone-related protein (PTHrP), without requiring direct skeletal metastases
- nih.gov
It affects the skeletal and renal systems through the tumor-driven secretion of circulating factors, overwhelmingly parathyroid hormone-related protein (PTHrP), without requiring direct skeletal metastases
- nih.gov
Clinically and pathophysiologically, circulating PTHrP binds to parathyroid hormone receptors, triggering profound osteoclastic bone resorption and stimulating renal tubular calcium reabsorption while promoting phosphate wasting, which leads to severe, often life-threatening elevations in serum calcium
- nih.gov
Clinically and pathophysiologically, circulating PTHrP binds to parathyroid hormone receptors, triggering profound osteoclastic bone resorption and stimulating renal tubular calcium reabsorption while promoting phosphate wasting, which leads to severe, often life-threatening elevations in serum calcium
Personalize your experience
Follow Humoral hypercalcemia of malignancy and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.